Trethera to present TRE-515 optic neuritis data at LABEST 2026
Trethera Corporation will present preclinical research on TRE-515, its oral inhibitor of deoxycytidine kinase (dCK), at the 8th Annual Los Angeles Bioscience Ecosystem Summit on 21 May 2026. The poster, entered into the Pearl Cohen Scientific Poster Competition at the Luskin Conference Center, reports that TRE-515 improved visual acuity across multiple mouse models of optic neuritis — a rare autoimmune condition causing acute vision loss.
Optic neuritis (ON) affects more than 100,000 patients annually in the United States. Approximately 10% of those affected experience incomplete recovery of vision, and the condition is closely associated with multiple sclerosis. Current standard-of-care treatment relies on corticosteroids, which can accelerate short-term recovery but do not improve long-term visual outcomes or reduce MS conversion rates at five years. That gap in durable efficacy is what Trethera is positioning TRE-515 to address.
The science and regulatory standing
TRE-515 targets dCK, the rate-limiting enzyme in the nucleoside salvage pathway — one of two biosynthetic routes cells use to generate DNA precursors. Research from UCLA's Clark laboratory, led by poster co-author and Associate Professor Peter Clark of the David Geffen School of Medicine, identified dCK as a key driver of aberrant T and B cell activation in autoimmune disease models including ON and inflammatory bowel disease. The oral capsule formulation is already in clinical development; the FDA has granted it Orphan Drug designation for ON and Fast Track designation for prostate cancer, suggesting a broad programme spanning oncology and neuroimmunology.
The company describes TRE-515 as first-in-class in the dCK inhibitor space, a characterisation that the preclinical data will need to bear out in human trials. Trethera has not disclosed the current clinical stage for the ON indication or published trial registration details in materials accompanying this announcement.
Market context and competitive landscape
The optic neuritis treatment landscape is attracting increased attention in part because of its link to MS. Several MS-focused biologics — including anti-CD20 agents and S1P-receptor modulators — have been evaluated for their ability to reduce relapse-associated optic nerve damage, but none is specifically approved for ON. The small annual patient population and incomplete-recovery subset represent a classic rare-disease commercial profile: high unmet need, regulatory incentives such as Orphan Drug designation, and limited competitive pressure at launch, provided clinical data hold up.
Trethera's dCK inhibition mechanism is mechanistically distinct from existing immunosuppressive approaches. Rather than broadly dampening immune signalling, it targets a metabolic checkpoint required by proliferating lymphocytes. A similar metabolic-targeting rationale has gained traction in oncology — where tumour cells can be preferentially dependent on the salvage pathway — but its translation to autoimmune neuroimmunology is relatively early. Investors and partnering pharmaceutical companies will look to the LABEST poster data, and any subsequent peer-reviewed publication, for reproducibility across animal model types and evidence of a safety margin at therapeutic doses.
What to watch
The 21 May presentation is a poster session rather than a late-breaking oral, which limits the immediate clinical and commercial signal. Nonetheless, LABEST draws more than 1,500 life sciences professionals, including venture capital firms and pharmaceutical business development teams, making it a meaningful visibility moment for a privately held company seeking its next financing round or partnership.
Key near-term milestones to track include: any disclosure of a Phase 1 or Phase 2 trial design for the ON indication; updated data from the prostate cancer Fast Track programme; and whether the company pursues a partnership or moves to raise further capital independently. Trethera did not provide a cash runway figure or named investors in this announcement.